Trial Condition(s):

Contraception

YAZ post authorization safety study (PASS)/post authorization efficacy study (PAES) in China

Bayer Identifier:

18261

ClinicalTrials.gov Identifier:

NCT02710708

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The primary objective is to assess the safety profile of YAZ in Chinese women, including adverse drug reactions (ADRs).
The secondary objectives are to investigate the rate of unintended pregnancies, the cycle control for subjects with and without preceding abortion, the bleeding pattern of subjects with and without preceding abortion (including the abortion-related bleeding pattern) and the efficacy in moderate acne vulgaris.
Another objective is to investigate the effect on dysmenorrhea.

Inclusion Criteria
-	Signed and dated informed consent
-	Chinese female subjects requesting oral contraception, including subjects who underwent abortion (medical or surgical) 
-	Planned use of combined oral contraceptives  for at least 6 cycles
-	Age:  18 to 45 years (inclusive); smokers must not be older than 35 years at the time of informed consent 
-	At least 4 weeks postpartum for women who are not breastfeeding or after a second trimester abortion
Exclusion Criteria
-	Evidence or suspicion of incomplete abortion (medical abortion subjects must have complete abortion confirmed by ultrasound [endometrial thickness ≤ 15 mm]).
-	Pregnancy or lactation
-	Menstrual disorders consistent with ovarian failure (eg, oligomenorrhea, amenorrhea, hypomenorrhea)
-	Abuse of alcohol, drugs, or medicine (eg, laxatives)
-	Inability to cooperate with the study procedures for any reason (eg, language comprehension, psychiatric illness, inability to get to the study site).
-	Any diseases or conditions that can compromise the function of body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication
-	Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
-	Any contraindication to YAZ according to the Chinese label, such as:
       -- Renal impairment
       -- Adrenal insufficiency
       -- A high risk of arterial or venous thromboembolic diseases.   Examples include subjects who are known to:
          --- Have deep vein thrombosis or pulmonary embolism, now or in the past 
          --- Have cerebrovascular disease 
          --- Have coronary artery disease 
          --- Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) 
          --- Have inherited or acquired hypercoagulopathies 
          --- Have uncontrolled hypertension 
          --- Have diabetes mellitus with vascular disease 
          --- Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 
       -- Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past 
       -- Liver tumors, benign or malignant, or liver disease 
-	Hypersensitivity to any ingredient of the study drug
-	Undiagnosed abnormal genital bleeding
-	Sterilized subjects or concomitant use of other hormonal contraception, intrauterine device (IUD), or intrauterine system (IUS) during the study
-	For subjects qualifying for the moderate acne subgroup:
       -- Subjects with acne and atopy, comedonal acne or acne conglobata, sandpaper acne or acne with multiple large nodes, cysts, fistular comedones, or abscessing fistular ducts
       -- Use of preparations that have an acne-inducing effect (eg, iodinated or bromated drugs, tuberculostatics, lithium, vitamin B1 [>1.5 mg daily], B6 [>2 mg daily], B12 [>6 µg daily], corticoids, adrenocorticotropic hormone anabolics, quinine, disulfiram, methoxypsoralene, phenobarbital, phenytoin, trimethadione, thyroid depressants, and certain oily cosmetics)
       -- Subjects undergoing systemic acne treatment

Trial Summary

Enrollment Goal
1921
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
YAZ (EE20/DRSP, BAY86-5300)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Shanghai, China, 200127

Status
Completed
 
Locations

Investigative Site

Urumchi, China

Status
Completed
 
Locations

Investigative Site

Guangzhou, China, 510623

Status
Completed
 
Locations

Investigative Site

Kunming, China, 650032

Status
Completed
 
Locations

Investigative Site

Weifang, China

Status
Completed
 
Locations

Investigative Site

hangzhou, China

Status
Completed
 
Locations

Investigative Site

Nanjing, China, 210006

Status
Completed
 
Locations

Investigative Site

Zibo, China

Status
Completed
 
Locations

Investigative Site

Beijing, China, 100191

Status
Completed
 
Locations

Investigative Site

Nanchang, China, 330006

Status
Completed
 
Locations

Investigative Site

Hangzhou, China, 310006

Status
Completed
 
Locations

Investigative Site

Beijing, China, 100853

Status
Completed
 
Locations

Investigative Site

Beijing, China, 100038

Status
Completed
 
Locations

Investigative Site

Beijing, China, 100034

Status
Completed
 
Locations

Investigative Site

Wenzhou, China, 325000

Status
Completed
 
Locations

Investigative Site

Changzhou, China, 213003

Status
Completed
 
Locations

Investigative Site

Xi'an, China, 710061

Status
Completed
 
Locations

Investigative Site

Hangzhou, China, 310016

Status
Completed
 
Locations

Investigative Site

Changsha, China

Status
Completed
 
Locations

Investigative Site

Taiyuan, China, 030001

Status
Completed
 
Locations

Investigative Site

Xiamen, China

Status
Completed
 
Locations

Investigative Site

Shanghai, China, 200040

Status
Completed
 
Locations

Investigative Site

shijiazhuang, China, 050035

Status
Completed
 
Locations

Investigative Site

Beijing, China, 100029

Status
Completed
 
Locations

Investigative Site

Tianjin, China, 300052

Status
Completed
 
Locations

Investigative Site

Nanjing, China, 210008

Status
Completed
 
Locations

Investigative Site

Wuxi, China, 214002

Status
Completed
 
Locations

Investigative Site

Wuhan, China, 430014

Status
Completed
 
Locations

Investigative Site

Liuzhou, China, 545006

Status
Completed
 
Locations

Investigative Site

Yueyang, China, 414000

Status
Completed
 
Locations

Investigative Site

Weifang, China, 261031

Status
Completed
 
Locations

Investigative Site

Chengdu, China, 610091

Status
Completed
 
Locations

Investigative Site

Kunming, China, 650011

Status
Completed
 
Locations

Investigative Site

Beijing, China, 100123

Status
Completed
 
Locations

Investigative Site

Guangzhou, China, 510405

Status
Completed
 
Locations

Investigative Site

Nanning, China, 530021

Status
Completed
 
Locations

Investigative Site

Shenzhen, China, 518036

Status
Completed
 
Locations

Investigative Site

Beijing, China, 100026

Status
Completed
 

Trial Design